Under a new licensing pact, Lonza's ADC subsidiary Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." As part of the accord, Synaffix is set to receive an undisclosed upfront payment as well potential milestone payments worth up to $1.3 billion. Source: Fierce Biotech 9/1/2025